Microsoft moves into genetic-data

  • 5 June 2009

Microsoft Corporation has made a move into genetic data management, following its acquisition of Rosetta Inpharmatics LLC, a subsidiary of pharmaceutical firm Merck & Co.

The Rosetta technology will be used to add genetic and genomic data management abilities to Microsoft’s recently announced Amalga Life Sciences effort.

The agreement calls for Microsoft and Merck to collaborate on software to improve drug discovery and development. Financial details were not disclosed.

Link

Rosetta Inpharmatics LLC

Microsoft Amalga

 

Subscribe to our newsletter

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Sign up

Related News

Harnessing AI and cybersecurity to transform healthcare in the UK

Harnessing AI and cybersecurity to transform healthcare in the UK

The UK healthcare sector is in a transformative era, driven by advancements in artificial intelligence (AI). AI has the potential to revolutionise healthcare by improving…
EU regulation: AI Act will mean a raft of new requirements for ‘high-risk’ systems

EU regulation: AI Act will mean a raft of new requirements for ‘high-risk’ systems

The new EU AI Act will have global reach – and a huge impact on the medtech and life sciences sector. By Sharon Lamb and…
Digital Health Coffee Time Briefing ☕

Digital Health Coffee Time Briefing ☕

This briefing includes ANS supporting the charity Facial Palsy UK by implementing Microsoft's Copilot service and a study around lethal heart rhythms.